Financial Performance - For the six months ended June 30, 2023, the company reported revenue of approximately RMB 639.5 million, an increase of 15.2% compared to RMB 555.2 million for the same period in 2022[11]. - Gross profit for the same period was RMB 504.8 million, reflecting a growth of 14.3% from RMB 441.6 million year-on-year[9]. - The net profit attributable to the company's owners was approximately RMB 220.2 million, up 2.5% from RMB 214.8 million in the previous year[11]. - Operating profit for the six months ended June 30, 2023, was approximately RMB 255.2 million, an increase of about 7.3% from RMB 237.9 million in the same period of 2022[20]. - The company reported a profit for the period of RMB 214,784 thousand, compared to a profit of RMB 220,164 thousand for the same period in 2022, showing a decline of about 2.2%[101]. - The company’s total comprehensive income for the period was RMB 211,081 thousand, slightly lower than RMB 214,596 thousand in the previous year, reflecting a decrease of approximately 1.9%[101]. Revenue Breakdown - Revenue from the structural heart disease business was approximately RMB 243.9 million, up about 25.1% from RMB 194.9 million in the same period of 2022[15]. - Revenue from the peripheral vascular business was approximately RMB 362.7 million, an increase of about 14.6% from RMB 316.6 million in the same period of 2022[16]. - The company’s sales in mainland China accounted for approximately 80.4% of total revenue, down from 83.2% in the previous year[11]. - The company’s overseas sales grew by 34.4%, indicating successful market expansion efforts[11]. Assets and Liabilities - The company's total assets increased by 10.6% to RMB 4,081.9 million, compared to RMB 3,690.1 million as of December 31, 2022[9]. - The total current assets as of June 30, 2023, were approximately RMB 1,934.5 million, an increase from approximately RMB 1,396.7 million as of December 31, 2022[26]. - The current liabilities totaled approximately RMB 634.8 million as of June 30, 2023, compared to approximately RMB 584.7 million as of December 31, 2022[26]. - The total liabilities as of June 30, 2023, were RMB 825,471 thousand, compared to RMB 769,046 thousand as of December 31, 2022, reflecting an increase of about 7.3%[110]. Research and Development - R&D expenses increased by approximately 10.3% to about RMB 110.6 million, with total R&D costs rising to approximately RMB 161.9 million, an increase of about 9.5%[19]. - The company aims to enhance its innovation and R&D capabilities to maintain industry leadership and expand global market share[43]. Investments and Financing - The company invested RMB 10.0 million in a private equity fund managed by Fuxin Capital, with a fair value of approximately RMB 10.1 million as of June 30, 2023, accounting for about 0.2% of total assets[21]. - The company agreed to invest USD 20.0 million (approximately RMB 144.4 million) in Ally Bridge Group Global Life Science Capital Partners V, with a fair value of approximately RMB 104.8 million as of June 30, 2023, representing about 2.6% of total assets[21]. - The company reported a net cash inflow from operating activities of RMB 223,128 thousand, compared to RMB 244,159 thousand for the same period in 2022, reflecting a decrease of approximately 8.6%[100]. Employee and Management - As of June 30, 2023, the group employed 1,391 full-time employees, an increase from 1,299 as of December 31, 2022[37]. - Total employee costs for the six months ended June 30, 2023, amounted to approximately RMB 182.8 million, compared to RMB 151.7 million for the same period in 2022[37]. - The total remuneration for key management personnel amounted to RMB 9,434,000 in 2023, up from RMB 7,660,000 in 2022, reflecting a growth of approximately 23.1%[167]. Corporate Governance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange and confirmed compliance for the six months ending June 30, 2023, with a noted deviation regarding the roles of Chairman and CEO being held by the same individual[44]. - The board consists of six members, including two executive directors, one non-executive director, and three independent non-executive directors, ensuring at least one independent director has appropriate professional qualifications[45]. - The company has confirmed that all board members complied with the securities trading standard code during the six months ending June 30, 2023[46]. Stock Options and Share Awards - The new stock option plan, effective from September 17, 2021, allows for the issuance of up to 462,929,240 shares, which is capped at 10% of the company's issued share capital as of that date[57]. - As of June 30, 2023, a total of 128,750,000 stock options were granted but not exercised under the stock option plan[66]. - The company has adopted the 2019 Share Award Scheme and the 2022 Share Award Scheme, which do not require shareholder approval[72]. - The maximum number of shares that can be awarded under the 2022 Share Award Plan is capped at 463,003,040 shares, which is 10% of the total issued shares as of March 3, 2022[82]. Government Grants and Subsidies - The company received government grants of RMB 11,720 thousand related to the acquisition of property and equipment, slightly lower than RMB 12,650 thousand received in the previous year[100]. - The company confirmed revenue from government grants of approximately RMB 8,971,000 for the six months ended June 30, 2023, up from RMB 7,050,000 in the same period of 2022[134]. Market Outlook - The company anticipates an upward trend in market demand for its products due to aging population and increased health awareness[35].
先健科技(01302) - 2023 - 中期财报